Neoparin (Enoxaparin Sodium)

Enoxaparin sodium binds to antithrombin III, greatly increasing its ability to inhibit activated factor Xa and, to a lesser extent, thrombin (factor IIa). By blocking factor Xa, the cascade that converts prothrombin to thrombin is interrupted, reducing fibrin clot formation while preserving a predictable anticoagulant profile.

The dose of Neoparin is individualized and set by the prescribing clinician based on the specific indication, patient weight, renal function, and risk factors. Dosing regimens differ for prophylaxis versus treatment and for subcutaneous versus intravenous administration, so the exact amount must be determined by a qualified health professional.

Safety data for enoxaparin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It may be used during pregnancy only when the potential maternal benefit justifies any possible risk to the fetus, and breastfeeding decisions should be made after consulting a healthcare provider.

To order Neoparin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain if needed), and assists with import documentation.

Neoparin (enoxaparin) is a low molecular weight heparin, offering more predictable pharmacokinetics, a longer half‑life, and once‑ or twice‑daily dosing compared with unfractionated heparin, which requires continuous infusion and frequent monitoring. Enoxaparin provides greater anti‑Xa activity, lower risk of heparin‑induced thrombocytopenia, and does not usually need routine laboratory monitoring.

Neoparin should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken vigorously. If temporary storage at controlled room temperature is necessary, keep the product in its original packaging and use it within the time frame specified by the manufacturer.

Neoparin is supplied as a sterile solution for subcutaneous injection or intravenous infusion. The route, injection site, and infusion rate are determined by the prescribing clinician based on the therapeutic indication and patient characteristics. Proper aseptic technique and correct needle length for subcutaneous administration are essential.

The most serious risks include major bleeding events such as intracranial or gastrointestinal hemorrhage, and heparin‑induced thrombocytopenia (HIT), which can paradoxically cause clot formation. Patients should be monitored for signs of unexpected bleeding, sudden drops in platelet count, or allergic reactions, and therapy should be stopped if these occur.

Neoparin is contraindicated in patients with active major bleeding, a known hypersensitivity to enoxaparin or other LMWHs, and those with a history of heparin‑induced thrombocytopenitis. Caution is also advised in individuals with severe renal impairment (creatinine clearance <30 mL/min) and in patients undergoing neuraxial anesthesia unless specific precautions are taken.